ERBB2 and breast carcinoma: Increased expression of Col10A1 has been a part of breast cancer signatures, including a CD10+ signature to discriminate in situ from invasive breast cancer [11] and a stroma expression signature to predict resistance to neoadjuvant chemotherapy in breast cancer [10], though the specific ER+/HER2+ subtype was not specifically evaluated.